MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial - 02/06/26
, Adrian Wai Chan, MD a, Daniel Moore-Palhares, MD a, Amir H Safavi, MD a, James Perry, MD b, Mary Jane Lim Fat, MD b, Eshetu G Atenafu, MSc c, Sunit Das, ProfMD d, Nir Lipsman, MD e, Chris Heyn, MD f, Pejman Maralani, MD f, Gregory J Czarnota, ProfMD PhD a, Mark Ruschin, PhD a, Brian Keller, PhD a, Angus Lau, PhD a, Hanbo Chen, MD a, Sten D Myrehaug, MD a, Hany Soliman, MD a, Chia-Lin Tseng, MD a, Arjun Sahgal, ProfMD aSummary |
Background |
Radiotherapy volumes for patients with glioblastoma have remained unchanged for decades and result in large volumes of irradiated brain. We aimed to show the safety of a small-margin, MRI-guided adaptive radiotherapy approach for glioblastoma.
Methods |
This single-arm, phase 2 trial was done at Sunnybrook Health Sciences Centre, Toronto, ON, Canada, and included patients with pathologically confirmed glioblastoma and planned for concurrent daily chemoradiotherapy up to 60 Gy in 30 daily fractions over 6 weeks (long course) or 40 Gy in 15 daily fractions over 3 weeks (short course). Eligible patients were adults (≥18 years) with an expected life expectancy greater than 12 weeks and an Eastern Cooperative Oncology performance status less than or equal to 2. A 5 mm clinical target volume (CTV) was applied, with the allowance of associated T2-weighted fluid-attenuated inversion recovery hyperintense regions in a personalised way at the discretion of the treating physician. All patients were treated with 1·5 T MRI–guided linear accelerator (MR-Linac) incorporating weekly gadolinium-enhanced online adaptive fractions. The primary outcome was the risk of marginal failure powered for non-inferiority with a margin of 10% compared with a historical control. All patients were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov , NCT04726397 .
Findings |
Between April 28, 2021, and May 12, 2023, 109 patients were assessed for eligibility and 98 were enrolled and received treatment on the UNITED protocol with 59 [60%] patients receiving long-course radiotherapy and 39 [40%] receiving short-course radiotherapy. Median follow-up was 14·2 months (IQR 8·9–19·7). 53 (54%) of 98 patients were male and 45 (46%) were female. The observed risk of marginal failure was 4% (95% CI 0–8). The most common grade 3–4 adverse events were lymphopenia (eight [11%] of 72 patients without baseline lymphopenia) and thrombocytopenia (four [4%] of 98 patients). Serious adverse events occurred in one (1%) patient due to febrile neutropenia and there were no treatment-related deaths.
Interpretation |
MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 27 - N° 6
P. 729-737 - juin 2026 Retour au numéro
Article précédent
- Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
- Shankar Siva, Muhammad Ali, Nicholas Hardcastle, Tomas Kron, Braden Higgs, Farshad Foroudi, Jeremy Ruben, Sree Appu, Jarad Martin, Swetha Sridharan, Rebecca Montgomery, Ryan Davey, Charles Lin, Mark Shaw, Sarat Chander, Mark Sidhom, Ben G L Vanneste, Declan G Murphy, Nathan Lawrentschuk, David Pryor, Simon Wood, Daniel Moon, Mathias Bressel
- International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study
- Eileen Morgan, Aude Bardot, Oliver Langselius, Mark J Rutherford, Hazem Abd Elkader, Damien Bennett, Aline Brennan, Oliver Bucher, John Butler, David A Cameron, Karen Canfell, Karen Chiam, Anna Chiarelli, Nicola Creighton, Prithwish De, Sue Evans, Deirdre Fitzpatrick, Marianne G Guren, Jack Hannah, Dyfed W Huws, Christopher G C A Jackson, Simon Mathis Kønig, Eshwar Kumar, Siri Larønningen, Mark Lawler, Qinwei Liu, Carol McClure, Asif Mehmood, Helen Mitchell, David S Morrison, Deirdre Murray, Todd Norwood, Karen A M Phillips, David Ransom, Lorraine Shack, Stephanie Smits, Nathalie Saint-Jacques, Luc te Marvelde, David Tran, Donna Turner, Giske Ursin, Sally Vernon, Meghan J Walker, Ryan R Woods, Bin Zhang, Freddie Bray, Isabelle Soerjomataram
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?